Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Aftab, S.O.; Ghouri, M.Z.; Masood, M.U.; Haider, Z.; Khan, Z.; Ahmad, A.; Munawar, N.
    Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach (2020), J. Transl. Med., 18, 275 .
    View publication on PubMedView publication on EuropePMC

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.7.7.48 galidesivir
-
 Severe acute respiratory syndrome coronavirus 2

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn Severe acute respiratory syndrome coronavirus 2
-
 diphosphate + RNAn+1
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
2.7.7.48 Severe acute respiratory syndrome coronavirus 2 P0DTD1 replicase polyprotein 1ab; SARS-CoV-2
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.7.7.48 nucleoside triphosphate + RNAn
-
 Severe acute respiratory syndrome coronavirus 2 diphosphate + RNAn+1
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.7.7.48 RDRP
-
 Severe acute respiratory syndrome coronavirus 2
2.7.7.48 RNA-dependent RNA polymerase
-
 Severe acute respiratory syndrome coronavirus 2

General Information

EC Number General Information Comment Organism
2.7.7.48 drug target analysis of the enzyme as a potential therapeutic drug target using a computational approach. Targeting the RdRpactive sites, ASP760 and ASP761, by antiviral drugs could be a potential therapeutic option for inhibition of coronavirus RdRp, and thus viral replication. Target-based virtual screening and molecular docking results show that the antiviral Galidesivir and its structurally similar compounds show promise against SARS-CoV-2. CID123624208 and CID11687749 may be considered for in vitro and in vivo clinical trials Severe acute respiratory syndrome coronavirus 2